carbonic acid 4-nitro-phenyl ester pent-4-enyl ester | 911040-72-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: carbonic acid 4-nitro-phenyl ester pent-4-enyl ester
• 英文别名: 4-Nitrophenyl pent-4-enyl carbonate；(4-nitrophenyl) pent-4-enyl carbonate
• CAS: 911040-72-7
• 化学式: C₁₂H₁₃NO₅
• 分子量: 251.239
• InChiKey: HYWWBSFSTBJAGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  81.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  carbonic acid 4-nitro-phenyl ester pent-4-enyl ester 、 (R)-4-((2R,4R,6R)-4-amino-2-methoxy-6-(pent-4-enyl)-tetrahydro-2H-pyran-2-yl)-3-(4-methoxybenzyl)thiazolidin-2-one 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以83%的产率得到pent-4-enyl (2R,4R,6R)-2-methoxy-2-((R)-3-(4-methoxybenzyl)-2-oxothiazolidin4-yl)-6-(pent-4-enyl)-tetrahydro-2H-pyran-4-ylcarbamate
  参考文献：
  名称：

  Cytoskeletal active compounds, compositions and use

  摘要：

  本发明涉及与天然拉曲林A或拉曲林B相关的合成细胞骨架活性化合物。本发明还涉及包含这些化合物和药用可接受载体的药物组合物。该发明还涉及一种预防或治疗与肌动蛋白聚合有关的疾病或症状的方法。在该发明的一个实施例中，该方法治疗增加的眼内压，如原发性开角型青光眼。该方法包括向受试者施用公式I或II的细胞骨架活性化合物的治疗有效量，其中所述量有效地影响细胞骨架，例如通过抑制肌动蛋白聚合。

  公开号：

  US20060217427A1

文献信息

• [EN] MACROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS<br/>[FR] COMPOSÉS MACROCYCLIQUES EN TANT QU'INHIBITEURS DE L'INTÉGRASE DU VIH
  申请人：MERCK SHARP & DOHME

  公开号：WO2014011769A1

  公开（公告）日：2014-01-16

  The present invention relates to Macrocyclic Compounds. The present invention also relates to compositions comprising at least one Macrocyclic Compound, and methods of using the Macrocyclic Compounds for treating or preventing HIV infection in a subject.

  本发明涉及大环化合物。本发明还涉及包含至少一种大环化合物的组合物，以及利用这些大环化合物治疗或预防受试者的HIV感染的方法。
• MACROCYCLIC COMPOUNDS AS HIV INTEGRASE INHIBITORS
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20150203512A1

  公开（公告）日：2015-07-23

  The present invention relates to Macrocyclic Compounds. The present invention also relates to compositions comprising at least one Macrocyclic Compound, and methods of using the Macrocyclic Compounds for treating or preventing HIV infection in a subject.

  本发明涉及大环化合物。本发明还涉及包含至少一种大环化合物的组合物，以及利用这些大环化合物治疗或预防受试者的HIV感染的方法。
• CYTOSKELETAL ACTIVE COMPOUNDS, COMPOSITION AND USE
  申请人：Lampe W. John

  公开号：US20080076735A1

  公开（公告）日：2008-03-27

  The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

  本发明涉及合成的细胞骨架活性化合物，其与天然拉曲林A或拉曲林B相关。本发明还涉及包含这种化合物和药学上可接受的载体的制药组合物。此外，本发明还涉及一种预防或治疗与肌动蛋白聚合有关的疾病或病症的方法。在本发明的一种实施例中，该方法治疗增加的眼内压，如原发性开角型青光眼。该方法包括向受试者给予公式I或II的细胞骨架活性化合物的治疗有效量，其中该量对细胞骨架产生影响，例如通过抑制肌动蛋白聚合。
• Multivalent Heterobifunctional Polymers And Methods Of Their Use
  申请人：Bundle David R.

  公开号：US20100166695A1

  公开（公告）日：2010-07-01

  Designed herein are multivalent heterobifunctional polymers for binding to a biological target exhibiting biological activity and to an effector template which can affect the biological activity of the biological target or detect the presence of the biological target. The polymers comprise a plurality of pre-arranged heterobifunctional ligands connected thereto, and each heterobifunctional ligand comprises a first functionality capable of binding to the biological target, and a second functionality capable of binding to the effector template. The heterobifunctional ligands are pre-arranged on the polymer so as to form a ternary complex between the polymer, the biological target and the effector template. The polymers, methods and compositions described herein provide an approach for the design and production of new therapeutic agents as well as agents useful in a variety of non-therapeutic applications.

  本文设计了一种多价异源双功能聚合物，用于与表现出生物活性的生物靶标和能够影响生物靶标生物活性或检测生物靶标存在的效应模板结合。聚合物包括多个预先排列的异源双功能配体，每个异源双功能配体包括能够结合生物靶标的第一功能和能够结合效应模板的第二功能。异源双功能配体在聚合物上预先排列，以形成聚合物、生物靶标和效应模板之间的三元复合物。本文所描述的聚合物、方法和组合物提供了一种设计和生产新治疗剂以及在各种非治疗应用中有用的剂的方法。
• Cytoskeletal active compounds, composition and use
  申请人：Inspire Pharmaceuticals, Inc.

  公开号：US08039465B2

  公开（公告）日：2011-10-18

  The present invention is directed to synthetic cytoskeletal active compounds that are related to natural Latrunculin A or Latrunculin B. The present invention is also directed to pharmaceutical compositions comprising such compounds and a pharmaceutically acceptable carrier. The invention is additionally directed to a method of preventing or treating diseases or conditions associated with actin polymerization. In one embodiment of the invention, the method treats increased intraocular pressure, such as primary open-angle glaucoma. The method comprises administering to a subject a therapeutically effective amount of a cytoskeletal active compound of Formula I or II, wherein said amount is effective to influence the cytoskeleton, for example by inhibiting actin polymerization.

  本发明涉及与天然拉曲林A或拉曲林B相关的合成细胞骨架活性化合物。本发明还涉及包含这样的化合物和药用载体的制药组合物。此外，本发明还涉及一种预防或治疗与肌动蛋白聚合有关的疾病或病症的方法。在本发明的一种实施方式中，该方法用于治疗增加的眼内压，例如原发性开角型青光眼。该方法包括向受试者施用公式I或II的细胞骨架活性化合物的治疗有效量，其中该量有效地影响细胞骨架，例如通过抑制肌动蛋白聚合。